Author: Simon

I am the Director of Research at Cure Parkinson's. Before that I was working as a Parkinson's research scientist at the University of Cambridge where I conducted both clinical- and lab-based research on Parkinson's. I have worked in the Parkinson's research field for over 15 years - both academically and in biotech ventures. All of my views/opinions expressed here are solely my own, and may not reflect the views of my employer or associated parties.

Arukiddingmab?

~ Simon ~ 13 Comments

# # # #

Today’s post is a work of fictional creative writing, because obviously no self-respecting, by-the-books, “public safety comes first” health care regulator would knowingly chose to put themselves into the ridiculous position herein described.

Call it a cautionary tale if you like.

Any aspects of this tale that sound remotely familiar to real world events are “reasonably likely” to be purely accidental and the work of the author’s warped ‘post-truth’ imagination. In reality, we all know that no health care regulator would be this foolish.

Surely.

# # # #

Source: Fraserinstitute

A Crazy Mess Carol

Stave one – The ghost of Crazy Mess past

A biotech company named Biowin had been developing a novel therapy for medical use called “Arukiddingmab”. After successful Phase 1 testing (the drug was well tolerated and exhibited some interesting preliminary data), the company approached the health regulator (the Government funded entity whose sole task is to ensure the public safety regarding medical therapies) and asked if they could skip the prudent Phase 2 “learn & confirm” stage of clinical testing, and jump directly into the critical test of efficacy Phase 3 step of clinical evaluation – to determine if their Arukiddingmab treatment was effective. The company had limited clinical data, but the move would help bring the treatment to patients quicker and of course save the company significant resources and time.

The regulator agreed to this idea, promoting it as a potential example of their “access accelerator” initiative. Biowin pressed ahead with their Phase 3 clinical programme, initiating 2 large trials involving several thousand people. As the trials rolled on, however, it became apparent to the independent data monitoring committee that the treatment was unlikely to demonstrate any effect. The initial data suggested that Arukiddingmab was having no impact compared to a placebo treatment. The independent data monitoring committee recommended stopping the trials, which Biowin reluctantly agreed to do. They made a press statement and the patient community expressed their disappointment.

Continue reading “Arukiddingmab?” →

Monthly Research Review – May 2021

~ Simon ~ Leave a comment

# # # #

At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during May 2021.

The post is divided into 10 parts based on the type of research:

# # # #

So, what happened during May 2021?

In world news:

May 5th – Tech company SpaceX successfully flew and landed their Starship prototype for the first time:

May 9th – The 100th anniversary of the birth of Sophie Scholl (Click here to learn more about her)

 

May 10th – A pan-coronavirus mRNA nanoparticle vaccine with activity against all major SARSCoV2 variants was described in the science journal ‘Nature’, showing potent effect in non-human primates (Click here to read more about this).

May 14th – The China National Space Administration landed its Zhurong rover at Utopia Planitia on Mars, making China the fourth country to land a spacecraft on the planet and the second to land a rover (Click here to read more about this).

May 26th – Oil company Shell became the first company to be legally mandated to align its carbon emissions with the Paris climate accord, following a landmark court ruling in the Netherlands (Click here to read more about this).

In the world of Parkinson’s research, a great deal of new research and news was reported:

In May 2021, there were 911 research articles added to the Pubmed website with the tag word “Parkinson’s” attached (5,459 for all of 2021 so far). In addition, there was a wave to news reports regarding various other bits of Parkinson’s research activity (clinical trials, etc).

The top 5 pieces of Parkinson’s news

Continue reading “Monthly Research Review – May 2021” →

Denali’s Phase I results

~ Simon ~ 4 Comments

# # # #

Leucine-rich repeat kinase 2 (or LRRK2) is a large, multi function protein that is associated with Parkinson’s. People with genetic variations in the region of DNA that provides the instructions for making LRRK2 protein have a higher risk of developing the condition.

In many cases of Parkinson’s, LRRK2 can become hyperactive. Researchers and biotech companies have been striving to identify drug-like molecules that can dampen down this hyperactivity in the hope of slowing down the progression of Parkinson’s.

One of the leading biotech firms in this area of research is Denali Therapeutics, and recently the company has provided some updates on their progress.

In today’s post, we will discuss what LRRK2 is, we will look at what Denali have achieved thus far, and we will review what the company has recently announced.

# # # #

Source: Denali

A presentation was given at the UBS 2021 Global Healthcare Virtual Conference this week by representatives from Denali Therapeutics.

The slide deck (which can be found here on the company’s website) touched on multiple lines of active research for the company, including their active clinical trial programs:

  • DNL310 (ETV:iduronate-2-sulfatase (IDS) for Hunter syndrome), which has expanded testing in Phase 1/2 based on positive interim data
  • DNL343 (EIF2B activator indicated for ALS), which has had positive interim Phase 1 data, and the company is planning a Phase 1b study in ALS (Click here to read a recent SoPD post on EIF2B activation)
  • DNL788 (RIPK1 inhibitor targeted at ALS, Alzheimer’s, & Multiple Sclerosis … I’m really curious, why not PD?!?), which is in ongoing Phase 1 studies in healthy volunteers (in collaboration with Sanofi)
  • DNL758 (aka SAR443122; another RIPK1 inhibitor targeted at inflammation), currently recruiting participants for a Phase 2 study of lupus & in Phase 1 for COVID-19 lung disease (again in collaboration with Sanofi)

Source: Denali

But of particular interest to us here at SoPD HQ were the slides on their LRRK2 inhibitor clinical trial data.

Founded in 2013 by a group of former Genentech executives, San Francisco-based Denali Therapeutics is a biotech company which is focused on developing novel therapies for people suffering from neurodegenerative diseases.

Ex-Genentechers. Source: Medicalstartups

Although they have product development programs for other condition (such as Amyotrophic Lateral Sclerosis and Alzheimer’s disease), Parkinson’s is definitely one of their primary indications of interest.

The company has been leading the charge in the development of LRRK2 inhibitors as a potential therapeutic class for Parkinson’s and they have recently made some big announcements.

What are LRRK2 inhibitors?

Continue reading “Denali’s Phase I results” →

Unmasking LRRK2 and GBA

~ Simon ~ 4 Comments

# # # #

Connecting genetics and biology is complicated. Researchers around the world have struggled to determine what each functional region of DNA is doing individually, let alone in combination with other regions.

And sometimes when the output of combinations is examined, the results can be unexpected.

Recently, researchers looked at the consequences of having a particular combination of Parkinson’s-associated risk factors… and they were rather surprised by the results

In today’s post, we will review the report presenting their results and consider the potential implications of the findings.

# # # #

Bragging rights. Source: Howstuffworks

A while back, I became a little obsessed with peacock feathers.

I didn’t start collecting them and wearing them on Saturday night or anything like that. Rather, I just got really fascinated with how they develop. Each individual feather, that is.

I mean, look at them:

Source: Dreamingandsleeping

Like all organisms, they are wondrous feats of nature and biology – particularly the jewel-toned ocelli (plural) or eyespots (the vivid circular patterns that seem evenly spread along each feather).

Each ocellus (singular) is created via a combination of individual strands of the larger feather. And each strand is further made up of tiny individually coloured segments. When you get really up close and personal with those eyespots, they look like this:

Source: Wired

My obsession centered around “the how”.

How does each strand of the feather know when to start some blue or gold colouration (and when to stop) along those strands? And how do the individual strands coordinate and match up so perfectly to create the marvelous image of the ocellus?

This type of question applies to many areas of biology (for example, how does a regenerating tail of a gecko know when to stop growing?), but remember that at the end of each mating season, the peacock sheds (or molts) its feathers. So these carefully coordinated feathers have to re-grow each year!

Tell me that that is not remarkable.

Remarkable, but what does this have to do with Parkinson’s?

Continue reading “Unmasking LRRK2 and GBA” →

Monthly research review – April 2021

~ Simon ~ Leave a comment

# # # #

At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during April 2021.

The post is divided into 10 parts based on the type of research:

# # # #

So, what happened during April 2021?

In world news:

April 4th –

 

April 15th – Investigators in China and the United States reported the injection of human stem cells into primate embryos, to grow chimeras for up to 20 days (and the world asked “Why?!? What was the point?!?” – click here to read the report and click here to read the press summary).

April 18th – The Super league! (Just a really dumb idea – basically, when rich people have more dollars than sense)

April 19th – “117 years after the Wright brothers succeeded in making the first flight on our planet, Nasa’s Ingenuity helicopter has succeeded in performing this amazing feat on another world” – Thomas Zurbuchen, Nasa’s associate administrator for science

April 21st – No Super League! Following an outcry from football fans and the withdrawal of the English clubs, the Super League was placed “on standby” (yeah, good luck with that).

In the world of Parkinson’s research, a great deal of new research and news was reported:

In April 2021, there were 1,099 research articles added to the Pubmed website with the tag word “Parkinson’s” attached (4,548 for all of 2021 so far). In addition, there was a wave to news reports regarding various other bits of Parkinson’s research activity (clinical trials, etc).

The top 5 pieces of Parkinson’s news

Continue reading “Monthly research review – April 2021” →

UCB at ANN looks A-OK

~ Simon ~ 3 Comments

# # # #

Alpha synuclein is one of the most common proteins in our brains and it has long been associated with Parkinson’s. The protein appears to clump together forming dense clusters ( or “aggregates“) in the Parkinsonian brain, and this may be related to the progressive neurodegeneration.

Researchers have been desperately seeking small molecules that will break up (or dissociate) these aggregates in the hope that it will slow down the progression of PD and allow neurons to return to health.

One example of such a molecule is UCB0599, which is being clinically developed by the pharmaceutical company UCB. This week, UCB presented the first clinical results for UCB0599 from their Phase I trial.

In today’s post, we will look at what alpha synuclein is, review what is known about UCB0599, discuss the results of the study, and consider what comes next.

# # # #

Source: AAN

Last week at the 2021 American Academy of Neurology virtual meeting a poster was presented by the pharmaceutical company UCB.

Here at SoPD HQ, we have been eagerly awaiting these results.

They were the findings from the first Phase I clinical trial of a new molecule called UCB0599.

What is UCB0599?

UCB0599 is a brain-penetrant, oral small molecule alpha-synuclein misfolding inhibitor.

What does that mean?

Continue reading “UCB at ANN looks A-OK” →

ISRIB: The ISR InhiBitor

~ Simon ~ 4 Comments

# # # #

In December 2020, a research paper was published that drew a lot of attention.

It involved a molecule that reversed memory deficits in aged mice – even weeks after treatment has stopped.

The treatment involved inhibition of the integrated stress response.

In today’s post, we will explore what the integrated stress response is, review the data presented in new report, and consider what might happen next with this line of research (and be warned, there is quite a bit of biology to kick things off).

# # # #

Title: Small molecule cognitive enhancer reverses age-related memory decline in mice.
Authors: Krukowski K, Nolan A, Frias ES, Boone M, Ureta G, Grue K, Paladini MS, Elizarraras E, Delgado L, Bernales S, Walter P, Rosi S.
Journal: Elife. 2020 Dec 1;9:e62048.
PMID: 33258451                  (This report is OPEN ACCESS if you would like to read it)

This report was published in December 2020.

It starts with a quote:

“Of the capacities that people hope will remain intact as they get older, perhaps the most treasured is to stay mentally sharp” (Source)

The report then proceeds to describe an experiment in which a small drug-like molecule reverses memory deficits in aged mice, even weeks after treatment has stopped.

Wow! What was the treatment?

The molecule is an ‘integrated stress response‘ (or ISR) inhibitor that has conveniently been called ISRIB (or ISR InhiBitor).

What is ISR and why would the researchers be inhibiting it?

Continue reading “ISRIB: The ISR InhiBitor” →

500

~ Simon ~ 9 Comments

# # # #

I started writing about the research being conducted in Parkinson’s in 2014. 

If I’m honest, it was simply an experiment. Having failed to write the next great kiwi novel (think Katherine Mansfield, Margaret Mahy, Witi Ihimaera, Eleanor Catton, and most recently Rose Carlyle), to distract myself I started playing around with science writing to see if I liked it.

And what do ye know: I did

One thing led to another… and now there’s 500 posts on this thing called “The Science of Parkinson’s” (Click here for the full list). 

In today’s post, we will revisit some of the key moments and thoughts on that journey.

# # # #

MOMENT OF CONCEPTION

The Science of Parkinson’s began life in the clinic room in the photo above.

It is clinic room 1 at the Brain Repair Centre at the University of Cambridge.

Back in 2014, yours truly had been working as a postdoctoral research scientist in Prof Roger Barker‘s lab, and (this will sound cliché, but) after almost 15 years of researching the biology of the Parkinson’s, I realised that I didn’t have much practical experience with the disease itself. Kind of like a taxi driver who thinks he has memorised all the roads, but has never actually climbed behind the wheel and interacted with a stranger wanting to be driven somewhere.

So I volunteered to help out in the clinic once or twice a week, doing some of the cognitive assessments.

It was straight forward work – leading folks through the various standardised tests – but the experience was extremely enlightening. Not just because one saw the heterogeneity of cases and the impact that the condition has on a human body (over time, with periodic visits), but also the human side of the whole beastly thing. You met and got to know the people affected and their families. You learnt their stories and listened to their lived experience of PD. It was a fascinating experience – one which further energized my efforts in the lab.

Everything had been going smoothly for about 8-9 months…

And then Martin Taylor walked in.

Continue reading “500” →

Monthly research review – March 2021

~ Simon ~ 1 Comment

# # # #

At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during March 2021.

The post is divided into ten parts based on the type of research:

# # # #

So, what happened during March 2021?

In world news:

March 5th – The UK Government has offered “claps” and a 1% pay rise to NHS nurses. Minister of State for Mental Health, Suicide Prevention and Patient Safety, Nadine Dorries said that a 1% offer “is the most we think we can afford” (you can’t make this stuff up – click here to read more about it).

 

March 8th – British shoe company “Shoezone” announced that Terry Boot would be replacing Peter Foot as their next finance director (Source) – you really can’t make this stuff up!

 

March 8th – Japanese researchers discovered that a species of sea slug (Elysia cf. marginata) can regenerate it’s entire body from a decapitated head (Click here to read more about this).

March 16th – Scientists reported the discovery of a new unknown bacteria species of Methylobacterium (designated IF7SW-B2T, IIF1SW-B5, and IIF4SW-B5). They were discovered… on the International Space Station (Source).

 

March 18th – COVID-19 pandemic: The number of vaccinations administered worldwide exceeded 400 million.

 

March 21st – Twitter turned 15 years old (makes one feel kinda… – click here to read more about this).

 

March 25 – COVID-19 pandemic: The number of vaccinations administered worldwide exceeds 500 million.

In the world of Parkinson’s research, a great deal of new research and news was reported:

In March 2021, there were 986 research articles added to the Pubmed website with the tag word “Parkinson’s” attached (3,449 for all of 2021 so far). In addition, there was a wave to news reports regarding various other bits of Parkinson’s research activity (clinical trials, etc).

The top 5 pieces of Parkinson’s news

Continue reading “Monthly research review – March 2021” →

Synucleinopathy begets channelopathy?

~ Simon ~ 1 Comment

# # # #

Alpha synuclein is a protein that is closely associated with Parkinson’s. It was the first gene to be associated with increased risk of developing Parkinson’s, and the alpha synuclein protein was found to be present in Lewy bodies – a characteristic feature of the Parkinson’s brain.

As a result of this association, researcher have used high levels of this protein to model Parkinson’s in cell culture and animal experiments. 

Recently, scientists have reported that high levels of alpha synuclein can cause shrinkage of motorneurons, resulting in a reduction of gut motility in mice – potentially connecting multiple features of Parkinson’s in one study.

In today’s post, we will review the results of this new study and consider what could happen next.

# # # #

Channelopathy conditions. Source: Frontiers

A reader recently emailed me to ask if Parkinson’s is a channelopathy?

It’s a good question.

What is a channelopathy?

Channelopathies are conditions caused by disruption of the function of proteins involved in ion channels or the proteins that regulate them. These diseases can be either congenital (present from birth, often resulting from a genetic mutation) or acquired (often resulting from an insult such as autoimmune attack or toxin on a particular type of ion channel – click here to read a good review on this topic).

Hang on a second, what are ion channels?

Ion channels are protein structures in membranes that allow certain elements to pass through them into (or out of) the interior of a cell.

Source: Biologydictionary

These conduits play critical roles in many processes of normal cellular life – from passing signals between cells to general cellular well being (homeostasis). Many of these channels are very selective in what they allow to pass (for example, there are calcium channels and sodium channels which only allow calcium and sodium to pass, respectively).

When components of a channel are disrupted (resulting in dysfunctional activity in that channel), it can have serious implications for cells and the organisms that they inhabit.

Can you give an example of a disease that is a channelopathy?

Spinocerebellar ataxia type 6 (or SCA6) can be used as an example of a channelopathy.

Spinocerebellar ataxia are a collection of rare, genetic condition that is characterized by slowly progressive cerebellar ataxia (a lack of muscle coordination that can make speech and movement difficult) and nystagmus (involuntary, uncontrollable eye movements).

This video explains what spinocerebellar ataxia are:

SCA6 is a late onset form of spinocerebellar ataxia (typically starting after 65 years of age) – many people with SCA6 can be misdiagnosed with ALS or Parkinson’s. SCA6 is caused by mutations in CACNA1A, a gene that provides the instructions for making one part (the alpha-1 subunit) of a calcium channel called CaV2.1.

Very interesting. But how does this relate to Parkinson’s?

Continue reading “Synucleinopathy begets channelopathy?” →